Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Chowdhury SR, Parikh CN, Kaur AN, DeMarco KD, Giwa HK, Mishra AK, Murphy KC, Zhou L, Ma B, Ye T, Li J, Liu H, Bai S, Johnson C, Simin K, Pitarresi JR, Zhu LJ, Watson EV, Kelliher MA, Green MR, Fitzgerald KA, Ruscetti M. PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors. Proc Natl Acad Sci U S A. 2025 Sep 30; 122(39):e2514948122.
-
Krieg AM. New insights into the role of IFN-a/? and TLR7/8/9 in cancer immunotherapy and systemic autoimmunity. J Immunother Cancer. 2025 Sep 18; 13(9).
-
Murata K, Minowa T, Tsukahara T, Yoshida T, Minami A, Nakatsugawa M, Mizue Y, Murai A, Tokita S, Sasaki K, Uhara H, Kubo T, Kanaseki T, Torigoe T, Hirohashi Y. An SNP-dependent cancer-testis antigenic epitope serves as a promising immunotherapeutic target for cancer. Oncoimmunology. 2025 Dec; 14(1):2528110.
-
Brazel D, Kazakova V, Fay M, Bollin K, Mittal K, Reynolds KL, Tsang M. Connecting the Dots: Practical Strategies for Academic and Community Oncology Synergy to Advance Multidisciplinary Management in Immunotherapy Toxicity Care. Am Soc Clin Oncol Educ Book. 2025 Jun; 45(3):e473080.
-
Skelly DA, Graham JP, Cheng M, Furuta M, Walter A, Stoklasek TA, Yang H, Stearns TM, Poirion O, Zhang JG, Grassmann JDS, Luo D, Flynn WF, Courtois ET, Chang CH, Serreze DV, Menghi F, Reinholdt LG, Liu ET. Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1 response. Cell Rep. 2025 May 27; 44(5):115698.
-
Sorroche BP, de Jesus Teixeira R, de Souza VG, Tosi IC, Tostes K, Laus AC, Santana IVV, de Lima Vazquez V, Arantes LMRB. CD24, NFIL3, FN1, and KLRK1 signature predicts melanoma immunotherapy response and survival. J Mol Med (Berl). 2025 Jun; 103(6):725-737.
-
Oka T, Smith SS, Oliver-Garcia VS, Lee T, Son HG, Mortaja M, Azin M, Garza-Mayers AC, Huang JT, Nazarian RM, Horn TD, Demehri S. Epigenomic regulation of stemness contributes to the low immunogenicity of the most mutated human cancer. Cell Rep. 2025 May 27; 44(5):115561.
-
Dora D, Revisnyei P, Pasic A, Galffy G, Dulka E, Mihucz A, Rosk? B, Szincsak S, Iliuk A, Weiss GJ, Lohinai Z. Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients. Front Immunol. 2025; 16:1543817.
-
Elyaman W, Stern LJ, Jiang N, Dressman D, Bradley P, Klatzmann D, Bradshaw EM, Farber DL, Kent SC, Chizari S, Funk K, Devanand D, Thakur KT, Raj T, Dalahmah OA, Sarkis RA, Weiner HL, Shneider NA, Przedborski S. Exploring the role of T?cells in Alzheimer's and other neurodegenerative diseases: Emerging therapeutic insights from the T Cells in the Brain symposium. Alzheimers Dement. 2025 Feb; 21(2):e14548.
-
Varanasi SK, Chen D, Liu Y, Johnson MA, Miller CM, Ganguly S, Lande K, LaPorta MA, Hoffmann FA, Mann TH, Teneche MG, Casillas E, Mangalhara KC, Mathew V, Sun M, Jensen IJ, Farsakoglu Y, Chen T, Parisi B, Deota S, Havas A, Lee J, Chung HK, Schietinger A, Panda S, Williams AE, Farber DL, Dhar D, Adams PD, Feng GS, Shadel GS, Sundrud MS, Kaech SM. Bile acid synthesis impedes tumor-specific T cell responses during liver cancer. Science. 2025 01 10; 387(6730):192-201.